{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:40:17Z","timestamp":1792104017453,"version":"4.4.0"},"reference-count":63,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>T-cell acute lymphoblastic leukemia (T-ALL) is biologically distinct from its B lymphoblastic (B-ALL) counterpart and shows different kinetic patterns of disease response. Although very similar regimens are used to treat T-ALL and B-ALL, distinctions in response to different elements of therapy have been observed. Similar to B-ALL, the key prognostic determinant in T-ALL is minimal residual disease (MRD) response. Unlike B-ALL, other factors including age, white blood cell count at diagnosis, and genetics of the ALL blasts are not independently prognostic when MRD response is included. Recent insights into T-ALL biology, using modern genomic techniques, have identified a number of recurrent lesions that can be grouped into several targetable pathways, including Notch, Jak\/Stat, PI3K\/Akt\/mTOR, and MAPK. With contemporary chemotherapy, outcomes for de novo T-ALL have steadily improved and now approach those observed in B-ALL, with approximately 85% 5-year event-free survival. Unfortunately, salvage has remained poor, with less than 25% event-free and overall survival rates for relapsed disease. Thus, current efforts are focused on preventing relapse by augmenting therapy for high-risk patients, sparing toxicity in favorable subsets and developing new approaches for the treatment of recurrent disease.<\/jats:p>","DOI":"10.1182\/asheducation-2016.1.580","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T11:05:27Z","timestamp":1480676727000},"page":"580-588","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":282,"title":["T-cell acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"2016","author":[{"given":"Elizabeth A.","family":"Raetz","sequence":"first","affiliation":[{"name":"Department of Pediatrics and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Teachey","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children\u2019s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"17","key":"2019111709062668900_B1","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood-2015-09-670729","article-title":"Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000","volume":"127","author":"M\u00f6ricke","year":"2016","journal-title":"Blood"},{"issue":"21","key":"2019111709062668900_B2","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1182\/blood.V124.21.3702.3702","article-title":"Improved outcome for children and young people with T-acute lymphoblastic leukaemia: Results of the UKALL 2003 Trial","volume":"124","author":"Patrick","year":"2014","journal-title":"Blood"},{"key":"2019111709062668900_B3","author":"Place","year":"2014"},{"issue":"16","key":"2019111709062668900_B4","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S1470-2045(15)00363-0","article-title":"Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial","volume":"16","author":"Place","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"2019111709062668900_B5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","article-title":"Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial","volume":"14","author":"Vora","year":"2013","journal-title":"Lancet Oncol"},{"issue":"23","key":"2019111709062668900_B6","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.794.794","article-title":"Capizzi-style methotrexate with pegasparagase (C-MTX) is superior to high-dose methotrexate (HDMTX) in T-lineage acute lymphoblastic leukemia (T-ALL): Results from Children\u2019s Oncology Group (COG) AALL0434 [abstract]","volume":"126","author":"Winter","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2019111709062668900_B7","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/sj.leu.2401555","article-title":"Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study","volume":"13","author":"Pullen","year":"1999","journal-title":"Leukemia"},{"issue":"26","key":"2019111709062668900_B8","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1200\/JCO.2005.05.047","article-title":"Molecular genetics of acute lymphoblastic leukemia","volume":"23","author":"Armstrong","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111709062668900_B9","first-page":"1212","article-title":"The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols","volume":"91","author":"van Grotel","year":"2006","journal-title":"Haematologica"},{"issue":"1","key":"2019111709062668900_B10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/sj.leu.2404957","article-title":"Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences","volume":"22","author":"van Grotel","year":"2008","journal-title":"Leukemia"},{"issue":"8","key":"2019111709062668900_B11","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","article-title":"Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study","volume":"118","author":"Schrappe","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111709062668900_B12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"issue":"10","key":"2019111709062668900_B13","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood-2002-08-2454","article-title":"Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children\u2019s Cancer Group","volume":"101","author":"Bostrom","year":"2003","journal-title":"Blood"},{"issue":"20","key":"2019111709062668900_B14","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","article-title":"Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children\u2019s Oncology Group Study AALL0232","volume":"34","author":"Larsen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111709062668900_B15","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2141.2005.05509.x","article-title":"Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial","volume":"129","author":"Mitchell","year":"2005","journal-title":"Br J Haematol"},{"issue":"8","key":"2019111709062668900_B16","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/leu.2011.84","article-title":"Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"25","author":"Teuffel","year":"2011","journal-title":"Leukemia"},{"issue":"8","key":"2019111709062668900_B17","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/(SICI)1097-0142(20000415)88:8<1964::AID-CNCR27>3.0.CO;2-1","article-title":"Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia","volume":"88","author":"Hurwitz","year":"2000","journal-title":"Cancer"},{"issue":"2","key":"2019111709062668900_B18","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/leu.2009.256","article-title":"Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001","volume":"24","author":"Mitchell","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"2019111709062668900_B19","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/asheducation-2014.1.198","article-title":"CNS prophylaxis in pediatric acute lymphoblastic leukemia","volume":"2014","author":"Sison","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10","key":"2019111709062668900_B20","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/ajh.23784","article-title":"Cranial radiation for pediatric T-lineage acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"89","author":"Kelly","year":"2014","journal-title":"Am J Hematol"},{"issue":"21","key":"2019111709062668900_B21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood.V120.21.133.133","article-title":"Low CNS relapse incidence without radiotherapy and improvement of outcome: results of subsequent EORTC-CLG 58881 and 58951 trials in pediatric T-cell acute lymphoblastic leukemia (ALL) [abstract]","volume":"120","author":"De Moerloose","year":"2012","journal-title":"Blood"},{"issue":"26","key":"2019111709062668900_B22","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation","volume":"360","author":"Pui","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111709062668900_B23","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1521-6926(03)00086-0","article-title":"Classification systems for acute and chronic leukaemias","volume":"16","author":"Szczepa\u0144ski","year":"2003","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"2019111709062668900_B24","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-2141.2011.08955.x","article-title":"Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children\u2019s Cancer Study Group Study L99-15","volume":"156","author":"Inukai","year":"2012","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111709062668900_B25","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11684-012-0224-4","article-title":"Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia","volume":"6","author":"Ma","year":"2012","journal-title":"Front Med"},{"issue":"3","key":"2019111709062668900_B26","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bjh.12882","article-title":"Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003","volume":"166","author":"Patrick","year":"2014","journal-title":"Br J Haematol"},{"issue":"21","key":"2019111709062668900_B27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V124.21.1.1","article-title":"T-lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in Children\u2019s Oncology Group (COG) Study AALL0434 [abstract]","volume":"124","author":"Wood","year":"2014","journal-title":"Blood"},{"issue":"22","key":"2019111709062668900_B28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood.V114.22.9.9","article-title":"Patients with early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL) have high levels of minimal residual disease (MRD) at the end of induction\u2014A Children\u2019s Oncology Group (COG) Study [abstract]","volume":"114","author":"Wood","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2019111709062668900_B29","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2010-06-292615","article-title":"Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children\u2019s Oncology Group (POG 9404)","volume":"118","author":"Asselin","year":"2011","journal-title":"Blood"},{"issue":"15","key":"2019111709062668900_B30","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children\u2019s Oncology Group","volume":"23","author":"Berg","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111709062668900_B31","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/pbc.25470","article-title":"Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children\u2019s Oncology Group Study AALL0434","volume":"62","author":"Winter","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2019111709062668900_B32","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2141.2008.07499.x","article-title":"Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria--a population-based report of the Austrian Berlin-Frankfurt-M\u00fcnster (BFM) Study Group","volume":"144","author":"Reism\u00fcller","year":"2009","journal-title":"Br J Haematol"},{"issue":"24","key":"2019111709062668900_B33","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2008.16.1414","article-title":"Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children\u2019s Oncology Group Study [corrected]","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111709062668900_B34","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood.V124.21.795.795","article-title":"Nelarabine in combination with etoposide and cyclophosphamide is active in first relapse of childhood T-acute lymphocytic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LL) [abstract]","volume":"124","author":"Whitlock","year":"2014","journal-title":"Blood"},{"key":"2019111709062668900_B35","first-page":"S137","article-title":"AALL07P1: Bortezomib with Reinduction Chemotherapy for First Relapse Pediatric ALL. A Children\u2019s Oncology Group Study","volume":"61","author":"Horton","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"2019111709062668900_B36","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1200\/JCO.2010.30.2877","article-title":"Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition","volume":"29","author":"Szczepanski","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111709062668900_B37","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bjh.12442","article-title":"Predicting relapse risk in childhood acute lymphoblastic leukaemia","volume":"162","author":"Teachey","year":"2013","journal-title":"Br J Haematol"},{"issue":"8","key":"2019111709062668900_B38","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.exphem.2015.05.017","article-title":"Novel biological insights in T-cell acute lymphoblastic leukemia","volume":"43","author":"Durinck","year":"2015","journal-title":"Exp Hematol"},{"issue":"1","key":"2019111709062668900_B39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/MOP.0000000000000171","article-title":"Update on biology and treatment of T-cell acute lymphoblastic leukaemia","volume":"27","author":"Patrick","year":"2015","journal-title":"Curr Opin Pediatr"},{"issue":"10","key":"2019111709062668900_B40","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1172\/JCI61269","article-title":"The molecular basis of T cell acute lymphoblastic leukemia","volume":"122","author":"Van Vlierberghe","year":"2012","journal-title":"J Clin Invest"},{"issue":"3","key":"2019111709062668900_B41","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2141.2011.08957.x","article-title":"T-cell acute lymphoblastic leukaemia: recent molecular biology findings","volume":"156","author":"Kraszewska","year":"2012","journal-title":"Br J Haematol"},{"issue":"23","key":"2019111709062668900_B42","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1182\/blood.V126.23.691.691","article-title":"The genomic landscape of childhood T-lineage acute lymphoblastic leukemia [abstract]","volume":"126","author":"Liu","year":"2015","journal-title":"Blood"},{"issue":"14","key":"2019111709062668900_B43","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1182\/blood-2009-07-234377","article-title":"Inactivation of LEF1 in T-cell acute lymphoblastic leukemia","volume":"115","author":"Gutierrez","year":"2010","journal-title":"Blood"},{"issue":"7380","key":"2019111709062668900_B44","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"issue":"19","key":"2019111709062668900_B45","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1182\/blood-2011-04-345595","article-title":"Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies","volume":"118","author":"Hogan","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111709062668900_B46","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nm.3078","article-title":"Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL","volume":"19","author":"Tzoneva","year":"2013","journal-title":"Nat Med"},{"issue":"19","key":"2019111709062668900_B47","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1182\/blood-2015-04-639138","article-title":"MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia","volume":"126","author":"Jones","year":"2015","journal-title":"Blood"},{"key":"2019111709062668900_B48","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fonc.2014.00170","article-title":"New Approaches to Target T-ALL","volume":"4","author":"Roti","year":"2014","journal-title":"Front Oncol"},{"key":"2019111709062668900_B49","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fped.2014.00054","article-title":"The challenge of targeting notch in hematologic malignancies","volume":"2","author":"Hernandez Tejada","year":"2014","journal-title":"Front Pediatr"},{"issue":"1","key":"2019111709062668900_B50","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nm.1900","article-title":"Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia","volume":"15","author":"Real","year":"2009","journal-title":"Nat Med"},{"key":"2019111709062668900_B51","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fonc.2014.00108","article-title":"Targeting the PI3K\/mTOR pathway in pediatric hematologic malignancies","volume":"4","author":"Tasian","year":"2014","journal-title":"Front Oncol"},{"issue":"21","key":"2019111709062668900_B52","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/onc.2012.347","article-title":"JAK\/STAT signaling in hematological malignancies","volume":"32","author":"Vainchenker","year":"2013","journal-title":"Oncogene"},{"issue":"10","key":"2019111709062668900_B53","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3324\/haematol.2015.130179","article-title":"Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia","volume":"100","author":"Vicente","year":"2015","journal-title":"Haematologica"},{"issue":"11","key":"2019111709062668900_B54","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood-2014-06-580480","article-title":"Efficacy of JAK\/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"key":"2019111709062668900_B55","doi-asserted-by":"crossref","first-page":"6604","DOI":"10.1038\/ncomms7604","article-title":"Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia","volume":"6","author":"Ma","year":"2015","journal-title":"Nat Commun"},{"issue":"4","key":"2019111709062668900_B56","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ccr.2012.09.016","article-title":"Therapeutic targeting of the cyclin D3:CDK4\/6 complex in T cell leukemia","volume":"22","author":"Sawai","year":"2012","journal-title":"Cancer Cell"},{"issue":"3","key":"2019111709062668900_B57","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1586\/era.13.4","article-title":"Proteasome inhibitors in acute leukemia","volume":"13","author":"Niewerth","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"2019111709062668900_B58","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/imr.12237","article-title":"Epigenetics in T-cell acute lymphoblastic leukemia","volume":"263","author":"Peirs","year":"2015","journal-title":"Immunol Rev"},{"issue":"4","key":"2019111709062668900_B59","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3109\/10428194.2013.823493","article-title":"Novel targeted therapies in acute lymphoblastic leukemia","volume":"55","author":"Portell","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2019111709062668900_B60","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111709062668900_B61","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/leu.2013.192","article-title":"STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention","volume":"28","author":"Dorritie","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2019111709062668900_B62","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/bjh.13852","article-title":"Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia","volume":"172","author":"Irving","year":"2016","journal-title":"Br J Haematol"},{"key":"2019111709062668900_B63","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fcell.2015.00016","article-title":"Targeting cell cycle regulators in hematologic malignancies","volume":"3","author":"Aleem","year":"2015","journal-title":"Front Cell Dev Biol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/580\/1251218\/hem088334.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/580\/1251218\/hem088334.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T09:06:53Z","timestamp":1573981613000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2016\/1\/580\/21136\/Tcell-acute-lymphoblastic-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2016.1.580","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}